StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Follistim AQ by Year

Follistim AQ (follitropin beta, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)

Merck Follistim AQ: -10.0% in FY2019, up 2.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2019
-10.0%
Period ended Dec 31, 2019
Change on a year earlier
+2.0 pts
-12.0% in FY2018
History
3 years
Since FY2017
Sources
3
Documents cited below

Where the FY2019 figure comes from

“|| Follistim AQ | 241 | 268 | -10 | 103 | 115 | -11 | 138 | 153 | -10”

Source: Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFollistim AQ (follitropin beta, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)Year on yearSource
FY2019Dec 31, 2019-10.0%+2.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 2018-12.0%0.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017-12.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Follistim AQ (%), annual FY2017–FY2019 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-follistim-aq-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.